On June 8, the full House passed the Medical User Fee Act by a vote 392-28. The legislation is a set of user fee agreements between the Food and Drug Administration (FDA) and medical device developers and manufacturers that must be reauthorized every five years.

With this legislation (part of a broader FDA user fee package) now through the House, eyes turn to the Senate where the Senate Health, Education, Labor and Pensions Committee will mark up its own version of the package on June 14.

ACC Chief Medical Officer Richard J. Kovacs, MD, MACC, testified before the House Energy and Commerce Committee back in April, with many of his main points – including the importance of advancing a patient-centric system and the necessity for diversity in clinical trials – reflected in the final version of the House bill. Read more about Kovacs’ testimony here. 

Keywords: Patient-Centered Care, Commerce, United States Food and Drug Administration, ACC Advocacy

< Back to Listings